Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation
J Roman, MA Alvarez, A Torres - Haematologica, 2000 - haematologica.org
BACKGROUND AND OBJECTIVES: Recent progress in the development of diagnostic
techniques has greatly facilitated the monitoring of minimal residual disease (MRD) in …
techniques has greatly facilitated the monitoring of minimal residual disease (MRD) in …
Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. The …
T Lion - Bone marrow transplantation, 1994 - europepmc.org
Recent progress in the development of diagnostic techniques has greatly facilitated the
monitoring of minimal residual disease (MRD) in patients with hematologic neoplasia. The …
monitoring of minimal residual disease (MRD) in patients with hematologic neoplasia. The …
Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation …
J Serrano, J Roman, J Sanchez… - Blood, The Journal …, 2000 - ashpublications.org
We studied lineage-specific chimerism and minimal residual disease (MRD) in sequential
posttransplant samples from 55 patients who underwent unmanipulated (n= 44) or partially T …
posttransplant samples from 55 patients who underwent unmanipulated (n= 44) or partially T …
Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation
JD Thompson, I Brodsky, JJ Yunis - 1992 - ashpublications.org
Residual disease remains a major problem in the treatment of human neoplasia. To
effectively monitor minimal leukemic activity after bone marrow transplantation (BMT), we …
effectively monitor minimal leukemic activity after bone marrow transplantation (BMT), we …
Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study
RT Costello, J Kirk, J Gabert - Leukemia & lymphoma, 1996 - Taylor & Francis
At present, allogeneic bone marrow transplantation (BMT) seems to be the only curative
treatment for patients with chronic myeloid leukemia (CML). The mechanisms of this …
treatment for patients with chronic myeloid leukemia (CML). The mechanisms of this …
Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow …
C Preudhomme, E Wattel, JL Lai, N Henic… - Leukemia & …, 1995 - Taylor & Francis
We prospectively performed repeated cytogenetic and PCR monitoring of residual disease
in all cases Ph positive of chronic myeloid leukemia (CML) allografted with non T cell …
in all cases Ph positive of chronic myeloid leukemia (CML) allografted with non T cell …
A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in …
AH Elmaagacli, K Runkel, N Steckel, B Opalka… - Bone marrow …, 2001 - nature.com
The detection of chimerism, residual molecular and cytogenetic disease following
transplantation of peripheral blood stem cells (PBSCT) with a nonmyeloablative conditioning …
transplantation of peripheral blood stem cells (PBSCT) with a nonmyeloablative conditioning …
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
We identified 103 consecutive patients who, 5 years after allogeneic transplantation for
chronic myeloid leukaemia (CML), were in molecular remission (MR). The 103 patients were …
chronic myeloid leukaemia (CML), were in molecular remission (MR). The 103 patients were …
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow …
G Martinelli, V Montefusco, N Testoni… - …, 2000 - haematologica.org
BACKGROUND AND OBJECTIVE: For purposes of therapeutic decision making, we used
quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with …
quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with …
Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help?
TP Hughes, JM Goldman - Bone marrow transplantation, 1990 - europepmc.org
The fate of the leukaemic clone after bone marrow transplantation (BMT) for patients with
chronic myeloid leukaemia (CML) may determine the long-term prognosis. Several groups …
chronic myeloid leukaemia (CML) may determine the long-term prognosis. Several groups …